Stefano Di Michele

ORCID: 0009-0005-9644-7919 · 12 papers in corpus
review 2026
Research and practice in thrombosis and haemostasis ·doi:10.1016/j.rpth.2026.106818

Heavy menstrual bleeding (HMB) is prevalent, with consequences impacting quality of life from adolescence through adulthood. Several clinical tools have been developed to aid in HMB diagnosis, which must be coupled with a detailed menstrual…

review 2026
Archives of gynecology and obstetrics ·doi:10.1007/s00404-026-08325-2

Growing evidence suggests that women with endometriosis may be particularly vulnerable to disordered eating behaviors (DEBs) and clinically defined eating disorders (EDs). This narrative review aims at integrating and critically analyzing t…

review 2026
European journal of obstetrics, gynecology, and reproductive biology ·doi:10.1016/j.ejogrb.2026.115465

PURPOSE: To synthesize current evidence on metabolomic alterations in women with adenomyosis and identify recurrent metabolic patterns that may clarify disease pathophysiology and support biomarker research. METHODS: PubMed/MEDLINE, Scopus…

case-report 2026
·doi:10.6084/m9.figshare.32049406.v1

To evaluate the clinical efficacy and safety of a once-daily oral fixed-dose combination of relugolix 40 mg, estradiol 1 mg, and norethisterone acetate 0.5 mg in women with symptomatic adenomyosis coexisting with uterine fibroids. This case…

case-report 2026
·doi:10.6084/m9.figshare.32049406

To evaluate the clinical efficacy and safety of a once-daily oral fixed-dose combination of relugolix 40 mg, estradiol 1 mg, and norethisterone acetate 0.5 mg in women with symptomatic adenomyosis coexisting with uterine fibroids. This case…

case-report 2026
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology ·doi:10.1080/09513590.2026.2659439

OBJECTIVE: To evaluate the clinical efficacy and safety of a once-daily oral fixed-dose combination of relugolix 40 mg, estradiol 1 mg, and norethisterone acetate 0.5 mg in women with symptomatic adenomyosis coexisting with uterine fibroids…

observational 2025
Advances in therapy ·doi:10.1007/s12325-025-03251-2

INTRODUCTION: This study aimed to evaluate metformin treatment's immediate and long-term efficacy in adolescent patients with polycystic ovary syndrome (PCOS) and hyperinsulinemia and the subsequent metabolic evolution post-treatment discon…

review 2025
Biomedicines ·doi:10.3390/biomedicines13020453

Background: Polycystic ovary syndrome (PCOS) is the most prevalent endocrinopathy in women of reproductive age, characterized by a broad spectrum of clinical, metabolic, and ultrasound findings. Over time, ultrasound has evolved into a corn…

review 2024
Journal of clinical medicine ·doi:10.3390/jcm13195677

Introduction: Endometriosis, characterized by the presence of endometrial tissue outside the uterus, includes deep endometriosis (DE), which can affect the urinary tract. Ureteral endometriosis (UE) is a rare but significant manifestation t…

2024
·doi:10.20944/preprints202402.1716.v1

Background: The validation of laser usage during laparoscopic procedures, notably by Camran Nezhat in the late 1980s, has been significant. Lasers offer precision and depth control in tissue vaporization without bleeding. Surgical intervent…

other 2024
Journal of clinical medicine ·doi:10.3390/jcm13061722

Background: The validation of laser usage during laparoscopic procedures, notably by Camran Nezhat in the late 1980s, has been significant. Lasers offer precision and depth control in tissue vaporization without bleeding. Surgical intervent…

review 2022
Journal of clinical medicine ·doi:10.3390/jcm11226727

In women with deep endometriosis, the spontaneous fertility rate might range from 2 to 10%. The optimal management of these women is still an area of debate. Therefore, this review aims to explore the literature on the impact of deep endome…